For decades, managing hyperkalemia in CKD and heart failure meant sacrificing optimal RAAS inhibition or relying on poorly tolerated binders. In this session, Dr. Yogesh Chhabra delivers a sharp, practical breakdown of how novel potassium binders are changing that dynamic. Learn how to navigate real-world dosing, manage acute-on-chronic elevations, and confidently maintain patients on guideline-directed medical therapy without trading cardio-renal benefit for potassium safety.